EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting Rap1b signaling cascades with CDNF: Mitigating platelet activation, plasma oxylipins and reperfusion injury in stroke

Jui-Sheng Wu, Helike Lõhelaid, Chih-Chin Shih, Hock-Kean Liew, Vicki Wang, Wei-Fen Hu, Yuan-Hao Chen, Mart Saarma, Mikko Airavaara, Kuan-Yin Tseng

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.09.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Jui-Sheng Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan. Hauptthemen laut MEDLINE: Platelet Activation, Signal Transduction, Stroke, Reperfusion Injury. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiwan Ministry of Science and Technology, Research Council of Finland, Sigrid Juséliuksen Säätiö.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cerebral reperfusion injury in stroke, stemming from interconnected thrombotic and inflammatory signatures, often involves platelet activation, aggregation and its interaction with various immune cells, contributing to microvascular dysfunction. However, the regulatory mechanisms behind this platelet activation and the resulting inflammation are not well understood, complicating the development of effective stroke therapies. Utilizing animal models and platelets from hemorrhagic stroke patients, our research demonstrates that human cerebral dopamine neurotrophic factor (CDNF) acts as an endogenous antagonist, mitigating platelet aggregation and associated neuroinflammation. CDNF moderates mitochondrial membrane potential, reactive oxygen species production, and intracellular calcium in activated platelets by interfering with GTP binding to Rap1b, thereby reducing Rap1b activation and downregulating the Rap1b-MAPK-PLA2 signaling pathway, which decreases release of the pro-inflammatory mediator thromboxane A2. In addition, CDNF reduces the inflammatory response in BV2 microglial cells co-cultured with activated platelets. Consistent with ex vivo findings, subcutaneous administration of CDNF in a rat model of ischemic stroke significantly reduces platelet activation, aggregation, lipid mediator production, infarct volume, and neurological deficits. In summary, our study highlights CDNF as a promising therapeutic target for mitigating platelet-induced inflammation and enhancing recovery in stroke. Harnessing the CDNF pathway may offer a novel therapeutic strategy for stroke intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet ActivationSignal TransductionStrokeReperfusion InjuryDisease Models, AnimalAnimalsHumansRatsMaleBlood Plateletsrap GTP-Binding ProteinsMicePlatelet Aggregation

Stichwörter der Autor:innen

CDNFRap1bcerebral dopamine neurotrophic factordMCAodistal middle cerebral artery occlusionischemic strokeoxylipin metabolismplatelet activation

Substanzen

rap GTP-Binding ProteinsRAP1B protein, human

Autor:innen und Institutionen

  • Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan.
  • Neuroscience Center, HiLIFE, University of Helsinki, 00014 Helsinki, Finland; Faculty of Pharmacy, University of Helsinki, 00014 Helsinki, Finland.
  • Department of Pharmacology, National Defense Medical Center, Taipei 114, Taiwan.
  • PhD Program in Pharmacology and Toxicology, Tzu Chi University, 970 Hualien County, Hualien, Taiwan; Neuro-Medical Scientific Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, 970 Hualien County, Hu…
  • Department of Neurological Surgery, Tri-Service General Hospital and National Defense Medical Center, Taipei 114, Taiwan.
  • PhD Program in Pharmacology and Toxicology, Tzu Chi University, 970 Hualien County, Hualien, Taiwan.

Förderung

  • Taiwan Ministry of Science and Technology
  • Research Council of Finland
  • Sigrid Juséliuksen Säätiö
  • Ministry of Science and Technology, Taiwan
  • Academy of Applied Science Inc
  • Tri-Service General Hospital
  • Technology Academy Finland
  • National Defense Medical Center

Zitieren

APA

Wu, J. S., Lõhelaid, H., Shih, C. C., Liew, H. K., Wang, V., Hu, W. F., Chen, Y. H., Saarma, M., Airavaara, M., & Tseng, K. Y. (2024). Targeting Rap1b signaling cascades with CDNF: Mitigating platelet activation, plasma oxylipins and reperfusion injury in stroke. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.09.005

Vancouver

Wu JS, Lõhelaid H, Shih CC, Liew HK, Wang V, Hu WF, et al. Targeting Rap1b signaling cascades with CDNF: Mitigating platelet activation, plasma oxylipins and reperfusion injury in stroke. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.09.005

BibTeX
@article{Wu2024,
  author = {Wu, Jui-Sheng and Lõhelaid, Helike and Shih, Chih-Chin and Liew, Hock-Kean and Wang, Vicki and Hu, Wei-Fen and Chen, Yuan-Hao and Saarma, Mart and Airavaara, Mikko and Tseng, Kuan-Yin},
  title = {Targeting Rap1b signaling cascades with CDNF: Mitigating platelet activation, plasma oxylipins and reperfusion injury in stroke},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.09.005}
}
Kostenlos starten →